<DOC>
	<DOCNO>NCT02172274</DOCNO>
	<brief_summary>Study determine pharmacokinetics BI 10773 total radioactivity include excretion mass balance , excretion pathway metabolism follow oral administration [ 14C ] BI 10773</brief_summary>
	<brief_title>BI 10773 Administered Oral Solution Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Healthy male accord complete medical history , include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead ECG ( electrocardiogram ) , clinical laboratory test Age 18 55 year , inclusive Body mass index 18.5 29.9 kg/m2 , inclusive Nonsmoker Signed date write informed consent prior admission study accordance GCP ( Good Clinical Practice ) local legislation Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal , psychiatric neurological disorder ( include form epilepsy ) Surgery gastrointestinal tract ( except appendectomy ) History relevant orthostatic hypotension , faint spell blackouts Subjects Gilbert 's Syndrome Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within one month prior administration trial drug Use prescription medication , overthecounter drug herbal preparation within 14 day prior administration trial drug Participation another trial investigational drug within two month prior administration trial drug trial History evidence habitual tobacco nicotine use within six month prior administration trial drug Alcohol abuse ( 60 g/day ) Drug abuse opinion investigator Blood donation ( 100 mL within four week prior administration trial drug trial ) Excessive physical activity within five day prior administration trial drug Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial centre A marked baseline prolongation QT/QTc interval ( correct QT interval ) ( e.g. , repeated demonstration QTc interval &gt; 450 m ) Male subject must agree minimise risk female partner become pregnant dosing day three month completion study . Acceptable method contraception male volunteer include vasectomy less three month prior dose , barrier contraception , medically accept contraceptive method . For female partner male volunteer , acceptable method contraception include intrauterine device , tubal ligation , hormonal contraceptive least two month , diaphragm spermicide Participation one radiolabeled investigational drug trial within one year prior administration trial drug . The previous radiolabeled trial drug must receive six month prior administration trial drug study , total exposure study previous study within recommend level consider safe , per 21 CFR ( Code Federal Regulations ) 361.1 ( eg , less 5000 mrem whole body annual exposure ) Irregular defecation pattern ( le one bowel movement day )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>